What is the best way to determine if you are developing the nation's most deadly condition, coronary artery disease (CAD)?

Data published today in The Lancet from ABSORB, the world’s first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.

Autopsies of individuals in one Minnesota County suggest that the decades-long decline in the rate of coronary artery disease may have ended and possibly reversed after 2000, according to a report in the February 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

A set of 15 proteins found in urine can distinguish healthy individuals from those who have coronary artery disease (CAD), a new study has found.

Mayo Clinic researchers discovered it is safe - and much more convenient and less costly -- for many patients to undergo coronary angiography and elective valve surgery on the same day, it is reported in the current issue of Mayo Clinic Proceedings.

New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.